Spotlight on Internal Medicine

Credits: 1.00 CME / CC
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Investigating the Role of New and Emerging Biologic Therapies
Michael S. Blaiss, MD
Vindico Medical Education

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Investigating the Role of New and Emerging Biologic Therapies

Start

Activity Details

Free CME/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABOHNS Continuing Certification
Released: April 30, 2021
Expires: April 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, immunologists, otolaryngologists, and other health care professionals involved in the management of patients with chronic rhinosinusitis with nasal polyps.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Examine the underlying pathophysiology and differentiation of chronic rhinosinusitis with nasal polyps (CRSwNP).
  • Review the rationale for the use of biologic therapies, including appropriate use in patients with CRSwNP who have had an inadequate response to conventional treatments.
  • Evaluate the clinical trial data of new and emerging biologic therapies based on their mechanisms of action, safety, and efficacy for the treatment of patients with CRSwNP.

Activity Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a challenge for otolaryngologists, allergists, and immunologists alike. This disease recurs in up to 80% of patients after sinus surgery followed by medical treatment, and about 40% of patients may need at least one further surgery over the next 10 years. The pathogenesis of CRSwNP is elusive, and differentiating subtypes is challenging. Emerging biologic therapies hold promise in treating this debilitating condition. In this interactive educational activity, the pathogenesis and treatment of CRSwNP is discussed by expert clinicians.

Agenda

Underlying Immunopathology of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Whitney W. Stevens, MD, PhD, FAAAAI

Overview of Treatment of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Michael S. Blaiss, MD

A Look at the Clinical Evidence of New and Emerging Biologics
Joseph K. Han MD, FARS, FAAAAI

Activity Chair

Michael S. Blaiss, MD
Clinical Professor of Pediatrics
Medical College of Georgia at Augusta University
Executive Medical Director, American College of Allergy, Asthma, and Immunology
Augusta, GA

Disclosure:
Consulting Fee: ALK, Covis, Merck, Pfizer, Sanofi/Regeneron

Faculty

Joseph K. Han MD, FARS, FAAAAI
Professor – Eastern Virginia Medical School
Norfolk, VA

Disclosure:
Consulting Fee: AstraZeneca, Genentech, GlaxoSmithKline, Intersect, Medtronic, OptiNose, Sanofi Genzyme

Whitney W. Stevens, MD, PhD, FAAAAI
Assistant Professor
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosure:
Consulting Fee: Bristol Myers Squibb, Genentech, GlaxoSmithKline
Speakers Bureau: GlaxoSmithKline

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s Continuing Certification program (formerly known as MOC). It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABOHNS Continuing Certification
Released: April 30, 2021
Expires: April 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, immunologists, otolaryngologists, and other health care professionals involved in the management of patients with chronic rhinosinusitis with nasal polyps.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Examine the underlying pathophysiology and differentiation of chronic rhinosinusitis with nasal polyps (CRSwNP).
  • Review the rationale for the use of biologic therapies, including appropriate use in patients with CRSwNP who have had an inadequate response to conventional treatments.
  • Evaluate the clinical trial data of new and emerging biologic therapies based on their mechanisms of action, safety, and efficacy for the treatment of patients with CRSwNP.

Activity Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a challenge for otolaryngologists, allergists, and immunologists alike. This disease recurs in up to 80% of patients after sinus surgery followed by medical treatment, and about 40% of patients may need at least one further surgery over the next 10 years. The pathogenesis of CRSwNP is elusive, and differentiating subtypes is challenging. Emerging biologic therapies hold promise in treating this debilitating condition. In this interactive educational activity, the pathogenesis and treatment of CRSwNP is discussed by expert clinicians.

Agenda

Underlying Immunopathology of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Whitney W. Stevens, MD, PhD, FAAAAI

Overview of Treatment of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Michael S. Blaiss, MD

A Look at the Clinical Evidence of New and Emerging Biologics
Joseph K. Han MD, FARS, FAAAAI

Activity Chair

Michael S. Blaiss, MD
Clinical Professor of Pediatrics
Medical College of Georgia at Augusta University
Executive Medical Director, American College of Allergy, Asthma, and Immunology
Augusta, GA

Disclosure:
Consulting Fee: ALK, Covis, Merck, Pfizer, Sanofi/Regeneron

Faculty

Joseph K. Han MD, FARS, FAAAAI
Professor – Eastern Virginia Medical School
Norfolk, VA

Disclosure:
Consulting Fee: AstraZeneca, Genentech, GlaxoSmithKline, Intersect, Medtronic, OptiNose, Sanofi Genzyme

Whitney W. Stevens, MD, PhD, FAAAAI
Assistant Professor
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosure:
Consulting Fee: Bristol Myers Squibb, Genentech, GlaxoSmithKline
Speakers Bureau: GlaxoSmithKline

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s Continuing Certification program (formerly known as MOC). It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Internal Medicine Presentations

1.00 CME / MOC / CNE
American Heart Association
W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor

W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor

Start

Activity Details

Free CME/MOC/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Released: September 13, 2021
Expires: September 12, 2022
60 minutes to complete

Accredited By

Target Audience

Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.

Learning Objectives

  1. Define Lipoprotein(a)
  2. Describe WHY Lipoprotein(a) should be measured
  3. Explain HOW to measure Lipoprotein(a)
  4. Indicate WHEN to measure Lipoprotein(a)

Activity Description

This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.

Statement of Educational Need

  • Clinicians lack knowledge about why they should measure Lipoprotein(a)
  • Clinicians do not know how to measure Lipoprotein(a)
  • Clinicians do not recognize when to measure Lipoprotein(a)

Faculty

Bart Duell, MD
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon

Disclosure: Akcea


Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York

Disclosure: Amgen, Inc.


Pia Kamstrup, MD, PhD
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark

Disclosure: None reported relevant to this webinar.


Calvin Yeang, MD, PhD
Cardiologist
UC San Diego Health
San Diego, California

Disclosure: Kaneka, Ionis Pharmaceuticals

Conflict of Interest Policy/Disclosure Statement

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

Statement of Commercial Support

This activity is supported by an educational grant from Kaneka Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.

Activity Details

Free CME/MOC/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Released: September 13, 2021
Expires: September 12, 2022
60 minutes to complete

Accredited By

Target Audience

Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.

Learning Objectives

  1. Define Lipoprotein(a)
  2. Describe WHY Lipoprotein(a) should be measured
  3. Explain HOW to measure Lipoprotein(a)
  4. Indicate WHEN to measure Lipoprotein(a)

Activity Description

This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.

Statement of Educational Need

  • Clinicians lack knowledge about why they should measure Lipoprotein(a)
  • Clinicians do not know how to measure Lipoprotein(a)
  • Clinicians do not recognize when to measure Lipoprotein(a)

Faculty

Bart Duell, MD
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon

Disclosure: Akcea


Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York

Disclosure: Amgen, Inc.


Pia Kamstrup, MD, PhD
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark

Disclosure: None reported relevant to this webinar.


Calvin Yeang, MD, PhD
Cardiologist
UC San Diego Health
San Diego, California

Disclosure: Kaneka, Ionis Pharmaceuticals

Conflict of Interest Policy/Disclosure Statement

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

Statement of Commercial Support

This activity is supported by an educational grant from Kaneka Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.

1.00 CME / CNE / CPE
Postgraduate Institute for Medicine
COVID-19: Keeping Up With a Moving Target – Treatment Updates for Hospitalists

COVID-19: Keeping Up With a Moving Target – Treatment Updates for Hospitalists

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: August 27, 2021
Expires: August 26, 2022
60 minutes to complete

Accredited By

Target Audience

Providers including hospital clinicians, intensivists, and others treating patients with COVID-19 in the hospital setting

Learning Objectives

  • Appraise the efficacy, safety, and indications for treatments for patients with COVID-19 requiring hospitalization.
  • Evaluate management strategies for outpatients with mild to moderate COVID-19.
  • Explain mechanisms of action of monoclonal antibodies (mAbs) and other current and in-development treatments for COVID-19.
  • Describe best practices for managing patients with COVID-19 with mAbs and other agents.

Activity Description

Drs. Paul Long and Paul G. Auwaerter discuss the latest news on treating COVID-19 patients in and out of the hospital.

Topics:

  • Test your knowledge with patient cases
  • Efficacy and safety of treatment options
  • The latest treatment guidelines and recommendations

Faculty

Paul G. Auwaerter, MD, MBA, FIDSA
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland


Paul Long, MD
Assistant Professor of Medicine
General Internal Medicine
Boston University School of Medicine
Boston, Massachusetts

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty/Presenter Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA

Verily (Scientific consulting)
EMD Serono (Scientific consulting)
JNJ (Equity holding)
Humanigen (DSMB)

Paul Long, MD
None

Planners and Managers
The PIM planners and managers have nothing to disclose.
The DKBmed planners and managers have nothing to disclose.
The IJHN Nurse Planner has nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Accreditation Statement
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement
This 1.0 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Statements will be awarded for this educational activity until August 27, 2022.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Faculty have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials, including COVID-19 convalescent plasma, monoclonal antibody treatments, tocilizumab, and dexamethasone.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: August 27, 2021
Expires: August 26, 2022
60 minutes to complete

Accredited By

Target Audience

Providers including hospital clinicians, intensivists, and others treating patients with COVID-19 in the hospital setting

Learning Objectives

  • Appraise the efficacy, safety, and indications for treatments for patients with COVID-19 requiring hospitalization.
  • Evaluate management strategies for outpatients with mild to moderate COVID-19.
  • Explain mechanisms of action of monoclonal antibodies (mAbs) and other current and in-development treatments for COVID-19.
  • Describe best practices for managing patients with COVID-19 with mAbs and other agents.

Activity Description

Drs. Paul Long and Paul G. Auwaerter discuss the latest news on treating COVID-19 patients in and out of the hospital.

Topics:

  • Test your knowledge with patient cases
  • Efficacy and safety of treatment options
  • The latest treatment guidelines and recommendations

Faculty

Paul G. Auwaerter, MD, MBA, FIDSA
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland


Paul Long, MD
Assistant Professor of Medicine
General Internal Medicine
Boston University School of Medicine
Boston, Massachusetts

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty/Presenter Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA

Verily (Scientific consulting)
EMD Serono (Scientific consulting)
JNJ (Equity holding)
Humanigen (DSMB)

Paul Long, MD
None

Planners and Managers
The PIM planners and managers have nothing to disclose.
The DKBmed planners and managers have nothing to disclose.
The IJHN Nurse Planner has nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Accreditation Statement
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement
This 1.0 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Statements will be awarded for this educational activity until August 27, 2022.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Faculty have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials, including COVID-19 convalescent plasma, monoclonal antibody treatments, tocilizumab, and dexamethasone.

0.50 CME / MOC
RMEI Medical Education, LLC
Overcoming Hurdles to Optimal Care for Patients with NTM-LD

Overcoming Hurdles to Optimal Care for Patients with NTM-LD

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Point(s)
Released: August 17, 2021
Expires: August 16, 2022
30 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ current data, guidelines, and best practices when managing individuals with nontuberculous mycobacterial lung disease (NTM-LD)
  • Apply strategies to maintain adherence and address treatment-related adverse effects in patients with NTM-LD

Activity Description

In this activity, a panel of experts discuss current guidelines and best practices for the management of nontuberculous mycobacterial lung disease (NTM-LD), including treatment options for refractory disease and strategies for minimizing adverse effects of therapies. An experienced patient with NTM-LD shares her experiences with oral and inhaled therapies and how she overcame treatment challenges.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Point(s)
Released: August 17, 2021
Expires: August 16, 2022
30 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ current data, guidelines, and best practices when managing individuals with nontuberculous mycobacterial lung disease (NTM-LD)
  • Apply strategies to maintain adherence and address treatment-related adverse effects in patients with NTM-LD

Activity Description

In this activity, a panel of experts discuss current guidelines and best practices for the management of nontuberculous mycobacterial lung disease (NTM-LD), including treatment options for refractory disease and strategies for minimizing adverse effects of therapies. An experienced patient with NTM-LD shares her experiences with oral and inhaled therapies and how she overcame treatment challenges.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

0.25 CME / MOC
RMEI Medical Education, LLC
A Guide to Expediting the Recognition & Diagnosis of NTM-LD

A Guide to Expediting the Recognition & Diagnosis of NTM-LD

Start
Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: July 28, 2021
Expires: July 27, 2022
15 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the factors that place patients at risk for developing nontuberculous mycobacterial lung disease (NTM-LD)
  • Use current guidelines to facilitate NTM-LD diagnosis

Activity Description

This learner-friendly, 15-minute infographic activity is augmented by expert and patient videos with an interactive approach to recognizing risk factors for nontuberculous mycobacterial lung disease (NTM-LD) and using guidelines to facilitate a timely diagnosis.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: July 28, 2021
Expires: July 27, 2022
15 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the factors that place patients at risk for developing nontuberculous mycobacterial lung disease (NTM-LD)
  • Use current guidelines to facilitate NTM-LD diagnosis

Activity Description

This learner-friendly, 15-minute infographic activity is augmented by expert and patient videos with an interactive approach to recognizing risk factors for nontuberculous mycobacterial lung disease (NTM-LD) and using guidelines to facilitate a timely diagnosis.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

0.75 CME / CNE / CPE
Postgraduate Institute for Medicine
Words Matter – Terms to Use and Avoid When Talking About Addiction

Words Matter – Terms to Use and Avoid When Talking About Addiction

Start

Activity Details

Free CME/CNE/CPE/CDE
0.75 AMA PRA Category 1 Credit(s)
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Released: July 15, 2021
Expires: October 17, 2022
45 minutes to complete

Provided By

Target Audience

This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Explain the effects of stigmatizing language on patients with addiction.
  • Compare common terminology and assess which terms should be used or avoided and why.
  • Integrate person-first, non-stigmatizing language into everyday practice.
  • Identify terms to use and terms to avoid when speaking to patients about addiction.

Activity Description

This CME/CE activity informs clinicians on how they can show leadership in how language can destigmatize the disease of addiction. It is focused on using person-first language, as well as terms to avoid to reduce stigma and negative bias when discussing addiction.

Course Director

Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose.

The following planners and others have nothing to disclose: Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the National Institute on Drug Abuse. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2678-H01-P)
Type of Activity: Knowledge

Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.

Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).

Statement of Commercial Support

There is no commercial funding for this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

Activity Details

Free CME/CNE/CPE/CDE
0.75 AMA PRA Category 1 Credit(s)
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Released: July 15, 2021
Expires: October 17, 2022
45 minutes to complete

Provided By

Target Audience

This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Explain the effects of stigmatizing language on patients with addiction.
  • Compare common terminology and assess which terms should be used or avoided and why.
  • Integrate person-first, non-stigmatizing language into everyday practice.
  • Identify terms to use and terms to avoid when speaking to patients about addiction.

Activity Description

This CME/CE activity informs clinicians on how they can show leadership in how language can destigmatize the disease of addiction. It is focused on using person-first language, as well as terms to avoid to reduce stigma and negative bias when discussing addiction.

Course Director

Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose.

The following planners and others have nothing to disclose: Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the National Institute on Drug Abuse. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2678-H01-P)
Type of Activity: Knowledge

Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.

Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).

Statement of Commercial Support

There is no commercial funding for this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

0.75 CME / CNE / CPE
Postgraduate Institute for Medicine
Your Words Matter – Language Showing Compassion and Care for Women, Infants, Families, and Communities Impacted by Substance Use Disorder

Your Words Matter – Language Showing Compassion and Care for Women, Infants, Families, and Communities Impacted by Substance Use Disorder

Start

Activity Details

Free CME/CNE/CPE/CDE
0.75 AMA PRA Category 1 Credit(s)
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Released: July 15, 2021
Expires: October 17, 2022
45 minutes to complete

Provided By

Target Audience

This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Explain the effects of stigmatizing language on patients with addiction.
  • Describe the effects of stigma on pregnant women and mothers.
  • Compare common terminology and assess which terms should be used or avoided and why.
  • Integrate person-first, non-stigmatizing language into everyday practice.
  • Identify terms to use and terms to avoid when speaking to patients about addiction.

Activity Description

This CME/CE activity highlights your role in helping destigmatize addiction and substance use disorder and reduce negative bias among pregnant women and mothers. The activity has background information and tips for providers on language to use or avoid.

Course Director

Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose.

The following planners and others have nothing to disclose: Hendree Jones, Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the National Institute on Drug Abuse. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2679-H01-P)
Type of Activity: Knowledge

Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.

Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).

Statement of Commercial Support

There is no commercial funding for this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

Activity Details

Free CME/CNE/CPE/CDE
0.75 AMA PRA Category 1 Credit(s)
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Released: July 15, 2021
Expires: October 17, 2022
45 minutes to complete

Provided By

Target Audience

This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Explain the effects of stigmatizing language on patients with addiction.
  • Describe the effects of stigma on pregnant women and mothers.
  • Compare common terminology and assess which terms should be used or avoided and why.
  • Integrate person-first, non-stigmatizing language into everyday practice.
  • Identify terms to use and terms to avoid when speaking to patients about addiction.

Activity Description

This CME/CE activity highlights your role in helping destigmatize addiction and substance use disorder and reduce negative bias among pregnant women and mothers. The activity has background information and tips for providers on language to use or avoid.

Course Director

Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose.

The following planners and others have nothing to disclose: Hendree Jones, Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the National Institute on Drug Abuse. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2679-H01-P)
Type of Activity: Knowledge

Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.

Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).

Statement of Commercial Support

There is no commercial funding for this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

1.00 CME / CNE / CPE
The Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part IV: Patient Cases: Putting Evidence Into Perspective

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part IV: Patient Cases: Putting Evidence Into Perspective

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Summarize the current guidelines and recommendations for the treatment of PAH
  • Develop individualized treatment regimens based on the multidisciplinary approach to care for PAH that takes into account treatment goals, short-and-long-term assessment, and comorbidities in order to improve patient outcomes

Faculty

Sonja Bartolome, MD, FCCP
Professor, Pulmonary and Critical Care Medicine
Associate Chief Quality Officer
UT Southwestern Medical Center
Dallas, TX

Dr. Bartolome discloses the following:
Consulting Fees: Janssen

Ronald J. Oudiz, MD, FACP, FACC, FCCP
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension, The Lundquist Institute
Torrance, CA

Dr. Oudiz discloses the following:
Consulting Fees: Gilead, Gossamer, Insmed, JnJ, Liquidia, Respira, United Therapeutics, V-Wave
Fees for Non-CME Services Received Directly from a Commercial Interest: JnJ, United Therapeutics, V-Wave
Contracted Research: AADi, Gossamer, Insmed, JnJ, Liquidia, United Therapeutics, V-Wave

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2782-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Summarize the current guidelines and recommendations for the treatment of PAH
  • Develop individualized treatment regimens based on the multidisciplinary approach to care for PAH that takes into account treatment goals, short-and-long-term assessment, and comorbidities in order to improve patient outcomes

Faculty

Sonja Bartolome, MD, FCCP
Professor, Pulmonary and Critical Care Medicine
Associate Chief Quality Officer
UT Southwestern Medical Center
Dallas, TX

Dr. Bartolome discloses the following:
Consulting Fees: Janssen

Ronald J. Oudiz, MD, FACP, FACC, FCCP
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension, The Lundquist Institute
Torrance, CA

Dr. Oudiz discloses the following:
Consulting Fees: Gilead, Gossamer, Insmed, JnJ, Liquidia, Respira, United Therapeutics, V-Wave
Fees for Non-CME Services Received Directly from a Commercial Interest: JnJ, United Therapeutics, V-Wave
Contracted Research: AADi, Gossamer, Insmed, JnJ, Liquidia, United Therapeutics, V-Wave

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2782-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

1.00 CME / CNE / CPE
The Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part I: Screening and Diagnosis of PAH

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part I: Screening and Diagnosis of PAH

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Identify patients with PAH based on symptoms, risk factors, and screening strategies outlined in evidence-based guidelines
  • Utilize evidence-based diagnostic methods to effectively and timely diagnose PAH patients

Faculty

Jean Elwing, MD, FCCP
Professor of Medicine
University of Cincinnati
Pulmonary Hypertension Program
Cincinnati, OH

Dr. Elwing discloses the following:
Consulting Fees: United Therapeutics, Acceleron, Liquidia, Altavant, Bayer, Gossamer Bio
Contracted Research: Actelion, Acceleron, Reata, United Therapeutics, Liquidia, Phase Bio, Complexa, Gossamer Bio, Bayer

Marc Humbert, MD, PhD
Centre National de Référence de l’Hypertension Pulmonaire Sévère
Hôpital Bicêtre
Assistance Publique – Hôpitaux de Paris
Université Paris-Saclay
Le Kremlin-Bicêtre, France

Dr. Humbert discloses the following:
Consulting Fees: Acceleron, Bayer, GSK, Janssen, Merck
Contracted Research: Acceleron, Bayer, GSK, Janssen, Merck

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2779-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Identify patients with PAH based on symptoms, risk factors, and screening strategies outlined in evidence-based guidelines
  • Utilize evidence-based diagnostic methods to effectively and timely diagnose PAH patients

Faculty

Jean Elwing, MD, FCCP
Professor of Medicine
University of Cincinnati
Pulmonary Hypertension Program
Cincinnati, OH

Dr. Elwing discloses the following:
Consulting Fees: United Therapeutics, Acceleron, Liquidia, Altavant, Bayer, Gossamer Bio
Contracted Research: Actelion, Acceleron, Reata, United Therapeutics, Liquidia, Phase Bio, Complexa, Gossamer Bio, Bayer

Marc Humbert, MD, PhD
Centre National de Référence de l’Hypertension Pulmonaire Sévère
Hôpital Bicêtre
Assistance Publique – Hôpitaux de Paris
Université Paris-Saclay
Le Kremlin-Bicêtre, France

Dr. Humbert discloses the following:
Consulting Fees: Acceleron, Bayer, GSK, Janssen, Merck
Contracted Research: Acceleron, Bayer, GSK, Janssen, Merck

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2779-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

1.00 CME / CNE / CPE
The Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part II: PAH Treatment - Goals, Therapeutic Options, and Guidelines

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part II: PAH Treatment - Goals, Therapeutic Options, and Guidelines

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Incorporate risk stratification methods for selecting and modifying therapy in patients with PAH
  • Evaluate the efficacy and safety of current and emerging therapeutic options for PAH
  • Review the evidence for initiating combination therapy in patients with PAH

Faculty

Nazzareno Galiè, MD
Professore Ordinario di Cardiologia
Direttore U.O.C. di Cardiologia, IRCCS-Policlinico di S.Orsola, Bologna
Direttore della Scuola di Specializzazione in
Malattie dell’Apparato Cardiovascolare
Bologna, Italy

Dr. Galiè discloses the following:
Consulting Fees: Janssen, Actelion, Ferrer, Pfizer
Contracted Research: Janssen

Gerald Simonneau, MD
French Reference Center for PH
Emeritus Professor University Paris-Saclay
Paris, France

Dr. Simonneau discloses the following:
Consulting Fees: Actelion, Bayer, MSA
Fees for Non-CME Services Received Directly from a Commercial Interest: Actelion, Bayer, MSA

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2780-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Incorporate risk stratification methods for selecting and modifying therapy in patients with PAH
  • Evaluate the efficacy and safety of current and emerging therapeutic options for PAH
  • Review the evidence for initiating combination therapy in patients with PAH

Faculty

Nazzareno Galiè, MD
Professore Ordinario di Cardiologia
Direttore U.O.C. di Cardiologia, IRCCS-Policlinico di S.Orsola, Bologna
Direttore della Scuola di Specializzazione in
Malattie dell’Apparato Cardiovascolare
Bologna, Italy

Dr. Galiè discloses the following:
Consulting Fees: Janssen, Actelion, Ferrer, Pfizer
Contracted Research: Janssen

Gerald Simonneau, MD
French Reference Center for PH
Emeritus Professor University Paris-Saclay
Paris, France

Dr. Simonneau discloses the following:
Consulting Fees: Actelion, Bayer, MSA
Fees for Non-CME Services Received Directly from a Commercial Interest: Actelion, Bayer, MSA

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2780-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

1.00 CME / CNE / CPE
The Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part III: Latest Data on PAH Treatment Approaches

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part III: Latest Data on PAH Treatment Approaches

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Evaluate the potential role of cardiac MRI metrics and other cardiac endpoints in PAH risk stratification
  • Interpret the results of recent trials for transition of PAH therapies
  • Summarize real-world data from PAH registries and their potential implications for management

Faculty

Vallerie V. McLaughlin, MD
Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI

Dr. McLaughlin discloses the following:
Consulting Fees: Acceleron, Actelion, Altavant, Caremark, Civi Biopharma, Gossamer, Liquida, United Therapeutics
Contracted Research: Acceleron, Actelion, Gilead, Sonivie, Reata, United Therapeutics

Stephan Rosenkranz, MD
Professor
Department of Cardiology, Pulmonology, and Intensive Care Medicine
Center for Molecular Medicine Cologne (CMMC)
Cologne Cardiovascular Research Center (CCRC)
Heart Center at the University of Cologne
Cologne, Germany

Dr. Rosenkranz discloses the following:
Consulting Fees and Fees for Non-CME Services Received Directly from a Commercial Interest: Abbott, Acceleron, Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Ferrer, United Therapeutics, Vifor
Contracted Research to Institution: Actelion, AstraZeneca, Bayer, Novartis, Pfizer, Janssen

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2781-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Evaluate the potential role of cardiac MRI metrics and other cardiac endpoints in PAH risk stratification
  • Interpret the results of recent trials for transition of PAH therapies
  • Summarize real-world data from PAH registries and their potential implications for management

Faculty

Vallerie V. McLaughlin, MD
Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI

Dr. McLaughlin discloses the following:
Consulting Fees: Acceleron, Actelion, Altavant, Caremark, Civi Biopharma, Gossamer, Liquida, United Therapeutics
Contracted Research: Acceleron, Actelion, Gilead, Sonivie, Reata, United Therapeutics

Stephan Rosenkranz, MD
Professor
Department of Cardiology, Pulmonology, and Intensive Care Medicine
Center for Molecular Medicine Cologne (CMMC)
Cologne Cardiovascular Research Center (CCRC)
Heart Center at the University of Cologne
Cologne, Germany

Dr. Rosenkranz discloses the following:
Consulting Fees and Fees for Non-CME Services Received Directly from a Commercial Interest: Abbott, Acceleron, Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Ferrer, United Therapeutics, Vifor
Contracted Research to Institution: Actelion, AstraZeneca, Bayer, Novartis, Pfizer, Janssen

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2781-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Pages